How does nicotinic acid modify the lipid profile?

European Heart Journal, Supplement

Volumn 8, Issue F, 2006, Pages

  Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Atherosclerosis; Dyslipidaemia; HDL cholesterol; Lipolysis; Niacin; Nicotinic acid

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; FATTY ACID; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROTIC PLAQUE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MACROPHAGE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33749001976     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul042     Document Type: Review

References (34)

1. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
2. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Institutes of Health/National Heart Lung and Blood Institute. www.nhlbi.nih. gov/guidelines/cholesterol(February 2006).
3. HeartScore Programme: the interactive tool for predicting and managing the risk of heart attack and stroke in Europe. http://www. escardio.org/ knowledge/decision_tools/heartscore (February 2006).
4. Risk assessment tool for estimating your 10-year risk of having a heart attack. http://hin.nhlbi.nih.gov/atpiii/calculator.asp (February 2006).
5. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741.
6. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
7. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28: 83-87.
8. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4:228-236.
9. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001;86:965-971.
10. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-1504.
11. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-288.
12. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-1534.
13. Stary HC, Chandler AB, Dinsmore, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
14. Pasterkamp C, Falk E. Atherosclerotic plaque rupture: an overview. J Clin Bas Cardiol 2000;3:81-86.
15. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004;44:2293-2300.
16. Brown G. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J 2005;7(Suppl.):F34-F40.
17. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-1934.
18. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 2000;267:1550-1564.
19. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955;54:558-559.
20. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355.
21. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-9874.
22. Karpe F, Frayn KN. The nicotinic acid receptor-a new mechanism for an old drug. Lancet 2004;363:1892-1894.
23. Boden G, Chen X, Capulong E, Mozzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001;50:810-816.
24. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13.
25. McGovern ME. Niaspan®: creating a new concept for raising HDL-cholesterol. Eur Heart J 2005;7(Suppl. F):F41-F47.
26. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6:179-188.
27. Superko RH. Lipoprotein subclasses and atherosclerosis. Front Biosci 2001;6:D355-D365.
28. Morgan JM, Capuzzi DM, Baksh RI, Intenzo C, Carey CM, Reese D, Walker K. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-1436.
29. Ogilvie D, Hamlet N. Obesity: the elephant in the corner. BMJ 2005;331:1545-1548.
30. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
31. Kastelein JJP. The realities of dyslipidaemia: what do the studies tell us? Eur Heart J 2005;7(Suppl. F):F27-F33.
32. Chapman MJ. Are the effects of statins on HDL-cholesterol clinically relevant? Eur Heart J 2004;6(Suppl. C):C58-C63.
33. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004;43:717-724.
34. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-1268.